|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||92.56 / 141.86|
Alexion Pharmaceuticals (ALXN) posted 2016 third-quarter results that surpassed Wall Street's expectations before today's market open.
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced the initiation of two Phase 3 trials of ALXN1210, a highly innovative, longer-acting anti-C5 antibody that inhibits terminal complement.
Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today announced financial results for the third quarter of 2016.
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that the U.
Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that the Company will report its financial results for the third quarter ended September 30, 2016 on Thursday, October 27, 2016 before the US financial markets...
Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) announced today that researchers presented new long-term data from an ongoing, open-label extension of the pivotal Phase 3 ARISE trial of Kanuma ® (sebelipase alfa) in...
The most recent short interest data has been released for the 09/15/2016 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that more than 1,500 employees around the world are volunteering in their respective communities as part of the Company's first Global Day of Service.
UnitedHealth becomes the second major healthcare provider to scratch the insulin product from its 2017 medicines roster.
In a study of analyst recommendations at the major brokerages, for the underlying components of the S&P 500, Alexion Pharmaceuticals Inc. has taken over the #117 spot from Zoetis Inc , according to ETF Channel.
TheStreet's Adam Feuerstein answers reader questions about Sarepta Therapeutics and its newly approved drug Exondys 51 for Duchenne muscular dystrophy.
Sarepta's largest shareholder talks about the company's future following FDA approval of its Duchenne muscular dystrophy drug.
Alexion Pharma (ALXN) stock coverage was started at FBR Capital on Thursday.
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced the launch of Uncommon Strength, a global campaign to raise awareness of rare diseases through the celebration of the extraordinary resilience and inner strength...
Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN) today announced that management will present at two upcoming investor conferences: Morgan Stanley Global Healthcare Conference in New York on Tuesday, September 13, 2016...
Investors once OK with waiting patiently for a Gilead rebound are growing frustrated, even angry, at the company's lack of progress.
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that the European Commission has granted orphan drug designation (ODD) to ALXN1007, a novel anti-inflammatory monoclonal antibody targeting complement protein C5a,...
The big bounce in Biogen's valuation over the past month would likely bake in a good chunk of the upside premium that could come from any takeover offer.
TheStreet highlights 3 stocks pushing the health care sector higher today.
Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today announced financial results for the second quarter of 2016.
TheStreet highlights 3 stocks pushing the health services industry lower today.
Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN) announced today that researchers presented new data from an ongoing open-label, Phase 1/2 trial of intravenous (IV) SBC-103 (rhNAGLU enzyme), an investigational enzyme replacement...
Alexion Pharmaceuticals (ALXN) stock was initiated with an "outperform" rating at RBC Captial earlier today as the firm expects the company 'to continue to dominate the rare disease space.'
Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that the Company will report its financial results for the second quarter ended June 30, 2016 on Thursday, July 28, 2016 before the US financial markets open.
Alexion (ALXN) stock is increasing in pre-market trading after Credit Suisse upped its rating to 'outperform' given its upside potential.
Here are Monday's top research calls, including an upgrade for GameStop, and downgrades for Baker Hughes, ConocoPhillips and Toll Brothers.
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that researchers presented new results from the REGAIN study, a global, placebo-controlled Phase 3 registration trial of eculizumab (Soliris ®) in patients...
Brexit volatility put a major damper on the global markets this month, and investors who owned these 10 S&P 500 stocks saw their profits shrink substantially in June.
TheStreet's Adam Feuerstein answers reader questions about biotech stocks.
Besides Sanofi, Biogen is the next most likely to complete a sizable transaction in the next 12 months, according to Credit Suisse analysts.
TheStreet’s Fundamentals of Investing Course will teach you the keys to making the right decisions in any market.
TheStreet’s Personal Finance Essentials Course will teach you money management basics and investing strategies to help you avoid major financial pitfalls.
TheStreet Courses offers dedicated classes designed to improve your investing skills, stock market knowledge and money management capabilities.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.